Table 4 Representative clinical-stage immunocytokines
From: Emerging new therapeutic antibody derivatives for cancer treatment
Name | Cytokine | Target | Format | Indication(s) | ClinicalTrials.gov identifier | Status |
|---|---|---|---|---|---|---|
L19IL2 | IL2 | Fibronectin ED-B | scFv-IL2 | Solid tumors Renal cell carcinoma | NCT01058538 | Phase I/II |
L19TNFa | TNFα | Fibronectin ED-B | scFv-TNFα | Solid tumors Colorectal cancer | NCT01253837 | Phase I/II |
F16IL2 | IL2 | Tenascin C | scFv-IL2 | Solid tumor Breast cancer Metastatic melanoma Non-small cell lung cancer | NCT01134250 | Phase Ib/II |
hu14.18-IL2 | IL2 | GD2 | IgG1-IL2 | Melanoma (skin) Neuroblastoma Sarcoma Unspecified childhood solid tumor | NCT00003750 | Phase II |
huKS-IL2 (EMD 273066) | IL2 | EpCAM | IgG-IL2 | Lung cancer Prostate cancer Ovarian cancer | NCT00132522 | Phase I |
DI-Leu16-IL2 (anti-CD20-IL2) | IL2 | CD20 | IgG-IL2 | B cell non-Hodgkin lymphoma | NCT01874288 | Phase I/II |
NHS-IL12 | IL12 | EpCAM | IgG-IL12 | Solid tumor Colon cancer Kaposi sarcoma | NCT04303117 | Phase I |
NHS-IL2-LT (EMD 521873) | IL2 | DNA/histone complex | IgG-IL2 | Lung cancer Non-small cell lung cancer | NCT00879866 | Phase I |
Anti-CEA-IL2v (cergutuzumab amunaleukin) | Variant of IL 2 | Carcinoembryonic antigen (CEA) | IgG-IL2 | Solid tumors | NCT02350673 | Phase I/II |
